CD163 and diffuse large B-cell lymphoma: The cut-off scores were used in Kaplan–Meier analysis; the results showed worse OS and PFS for DLBCL cases with ≥ 9.5% CD163+ M2 TAM compared with cases with < 9.5% CD163+ M2 TAM (5-year PFS rate, 37.9% versus 85.4%, Figure 3E) and OS (5-year OS rate, 55.90% versus 89.80%, Figure 4E).